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Although it has seen a decrease in incidence, gastric carcinoma is
still a significant cause of cancer death, with an overall 5-year
survival rate of approximately 15%, and 48% for patients with
complete (R0-UICC) resection of their tumour (Allum et al, 1989;
Bollschweiler et al, 1993; Roder et al, 1993). Even considering
epidemiological differences and earlier diagnoses, it still appears
that the more radical surgery routinely practiced in Japan may be
beneficial for patients with gastric carcinoma (Noguchi et al, 1989;
Bollschweiler et al, 1993; Bonenkamp et al, 1993; Thompson et al,
1993), although there is still some controversy regarding the
benefit of extended lymphadenectomy (Siewert et al, 1993;
Bonenkamp et al, 1995; Roder et al, 1995). One argument in
favour of extended lymphadenectomy is that microscopic deposits
of tumour can be frequently detected by immunohistochemistry in
perigastric lymph nodes, diagnosed by routine histological
methods to be free of tumour (Siewert et al, 1996).
Despite these extended procedures, tumour recurrence is not
infrequent in patients who have had a complete resection of their
gastric carcinoma. One of the most common (30—50%) (Boku et
al, 1990) and earliest forms of tumour recurrence is disseminated
peritoneal carcinosis, which predicts a very poor prognosis for the
patient (Spratt, 1986; Allum et al, 1989; Nakamura et al, 1992;
Thompson et al, 1993).
In past studies using conventional lavage cytology in patients
with a complete tumour resection, peritoneal carcinosis has been
shown to be more frequent when free peritoneal tumour cells were
detected preoperatively (Nakajima et al, 1978; Koga et al, 1984;
Asao et al, 1989; Jaehne et al, 1989; Iitsuka et al, 1990; Nishiyama
et al, 1995; Bonenkamp et al, 1996). For this reason, it was
recently proposed on a trial basis by the International Union
Against Cancer (UICC) (UICC, 1993) that tumours with conven-
tional cytological evidence of peritoneal involvement should be
classified as pM1, with the provision that this is a cytological
finding (Hermanek and Wittekind, 1995).
In general, the sensitivity for the detection of malignant cells in
effusions can be increased by a factor of two to three using immuno-
cytology (Johnston et al, 1987; Lidang Jensen and Johansen, 1994).
Specifically, very high degrees of sensitivity and specificity can be
achieved using the antibody Ber-Ep4 (Latza et al, 1990; De Angelis
et al, 1992; Stoop et al, 1992; Diaz-Arias et al, 1993; Robinson and
Royston, 1993). This antibody recognizes epithelial glycoproteins 34
and 49 kDa in size, found on the epithelial cell membrane, which
correspond to nidogen, a matrix adhesion protein (Simon et al, 1990).
Using Ber-Ep4 for tumour cell detection in peritoneal lavage
specimens, we carried out the present prospective study on a large
group of patients with completely resected gastric carcinoma to
answer the following questions: (1) how frequent is FPTC in
completely resected gastric carcinoma?; (2) does FPTC predict the
likelihood or pattern of tumour recurrence?; and (3) what impact
does FPTC have on patient survival?
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Summary We prospectively investigated the prognostic significance of free peritoneal tumour cells (FPTC) in a series of 118 patients with
completely resected gastric carcinoma. Immunocytochemistry with the monoclonal antibody Ber-Ep4 was performed on cytospins from
intraoperative peritoneal lavage specimens. Twenty-three patients (20%) had FPTC which was significantly correlated with pT and pN
categories, stage, tumour size, lymphatic invasion, Laurèn and WHO classifications and perigastric adipose tissue metastases. The median
survival time for all FPTC positive compared with negative patients was significantly shorter (11 compared with > 72 months), with estimated
5-year survival rates of 8% vs. 60%. None of the patients with FPTC had an early gastric cancer. In advanced tumour subgroups without and
with serosal invasion (n = 59 and 35), there were 19% and 34% with FPTC. Multivariate survival analysis showed nodal status, FPTC,
mesenteric lymphangiosis, and lymph node metastasis to the compartment III to be independent prognostic factors with relative risks of 6.6,
4.5, 2.9 and 2.2 respectively. Recurrent disease occurred in 91% of FPTC-positive and in 38% of FPTC-negative patients. FPTC had a
positive predictive value of 91% and a specificity of 97% for tumour recurrence. FPTC is a strong negative, independent prognostic indicator
for survival in gastric carcinoma.
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Patient study group
Between June of 1987 and December of 1990, 241 patients were
operated upon for a histologically confirmed gastric adenocarcinoma
at the Department of Surgery of the Technical University of Munich.
These patients are a subgroup of a larger study group which was
previously published as part of the German Gastric Carcinoma Study
Group (GGCSG) (Roder et al, 1993). One hundred and eighteen
patients were included in this prospective study who fulfilled the
following criteria: (1) an intraoperative peritoneal lavage yielding a
sample which was sufficient for diagnosis; (2) complete macroscopic
and histological removal of tumour (R0 resection); (3) no preopera-
tive chemotherapy; (4) a post-operative survival of at least 3 months
(to eliminate post-operative complications from survival analysis);
and (5) no other primary malignant tumour. These 118 patients
included 39 female and 79 male patients with an average age of 59
(range 31—79).
Operative procedure
The operative procedure was determined by the stage, location and
histological Laur￿n type according to the standardized protocols of
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Table 1 Free peritoneal tumour cells (FPTC) compared with TNM category
Variable Patients FPTC
n (%) Negative Positive Positive P-value
nn %
Tumour (pT)
T1 24 (20) 24 0 –
Mucosa 10 (8) 10 0 –
Submucosa 14 (12) 14 0 –
T2 59 (50) 48 11 (19)
Muscularis 25 (21) 22 3 (12)
Subserosa 20 (17) 14 6 (30)
Fat tissue 14 (12) 12 2 (14)
T3 22 (19) 13 9 (41)
T4 13 (11) 10 3 (23) 0.006a
Nodes (pN)
N0 49 (41) 46 3 (6)
N1 16 (14) 13 3 (19)
N2 53 (45) 36 17 (32) 0.004
Metastasis (pM)
M0 105 (89) 86 19 (18)
M1 (lymph) 13 (11) 9 4 (31) n.s.
Statistical analysis: chi-squared test; n.s. = not significant (P > 0.05); aT1/T2/T3/T4; staging of tumour according UICC, 1987 and
recommendations of UICC supplement 1993.
Table 2 Free peritoneal tumour cells (FPTC) compared with stage
Stage Category Patients FPTC
pTNM
n (%) Negative Positive Postive
nn (%)
IA pT1 N0 M0 23 (19) 23 0 –
IB pT1 N2 M0 – – – – –
pT2 N0 M0 22 (19) 20 2 (9)
II pT1 N2 M0 1 (1) 1 0 –
pT2 N1 M0 11 (10) 9 2 (18)
pT3 N0 M0 4 (3) 3 1 (25)
IIIA pT2 N2 M0 22 (19) 17 5 (23)
pT3 N1 M0 4 (3) 3 1 (25)
pT4 N0 M0 – – – – –
IIIB pT3 N2 M0 12 (10) 6 6 (50)
pT4 N1 M0 1 (1) 1 0 –
IV pT4 N2 M0 5 (4) 3 2 (40)
pT1–4 N1–2 M1 13 (11) 9 4 (31)
Statistical analysis: chi-squared test; P = 0.009: IA/IB/II/IIIA/IIIB/IV; staging of tumour according to UICC, 1987.the GGCSG (Roder et al, 1993; Siewert et al, 1993). Twenty-one
patients (18%) with a T1 or T2 tumour of the intestinal Laur￿n type
in the distal third of the stomach received a subtotal gastric resec-
tion. Fifty-one patients (43%) had a standard total gastrectomy.
Forty patients (34%) had an extended gastrectomy. Of these 40
patients, 20 (50%) had a transhiatal, 15 (38%) a left regional and
five (12%) both a transhiatal and left regional extension. The
remaining six patients (5%) had a resection of their gastric remnant
because of a stump carcinoma. Using the recommendations of the
Japanese Research Society for Gastric Cancer (JRSGC) (1981), the
lymph nodes of compartments I and II were completely removed by
an ￿en bloc￿ dissection. The lymph nodes of the hepatoduodenal
ligament (station 12) and the retroduodenal lymph nodes (station
13) of compartments III were routinely dissected in patients with
advanced (T2—T4) cancers (Siewert et al, 1993).
Staging and pathological data
The histopathological evaluation of the specimen followed the
recommendations of the GGCSG (Roder et al, 1993) with the TNM
classification performed according to the guidelines of the UICC
(UICC, 1993). Twenty-three of the tumours (19%) were classified
as stage IA, 22 (19%) as IB, 16 (14%) as II, 26 (22%) as IIIA, 13
(11%) as IIIB and 18 (15%) as stage IV tumours (see Table 2).
Pathological data included the location, size, histological type
according to the WHO (Watananbe et al, 1990), Borrmann (1926)
and Laur￿n (1965) classifications, grade of the primary tumour
and the presence or absence of vessel or perineural invasion, and
lymphangiosis carcinomatosa.
Follow-up data
None of the patients received adjuvant therapy. Approximately
40% of the patients were examined for tumour recurrence in the
tumour follow-up programme of the Department of Surgery at the
Klinikum rechts der Isar [including a clinical examination, routine
and tumour marker laboratory studies, abdominal ultrasound,
endoscopy, computerized tomography (CT) and bone scans] in 3-
month intervals during the first post-operative year and in 6-month
intervals thereafter. Suspected recurrent lesions were confirmed
histologically whenever possible. The remaining patients were
examined by outside physicians according to this same protocol
and the data collected at the Klinikum rechts der Isar. The follow-
up data included the location and time of the first tumour recur-
rence, additional therapy given, survival time, and date and cause of
death. None of the patients was lost to follow-up. Fifty-seven
patients (48%) died because of tumour recurrence. The median
survival time of these patients was 18 months. At the end of the
study period, 54 patients (46%) were still alive, the mean follow-up
time for these patients was 64 months with a range from 41 to 84
months. Seven patients (6%) died of other causes (three suicide,
two cardiovascular disease, one pneumonia, one iatrogenic oesoph-
agus perforation). All of these seven patients were negative for
FPTC. For survival analysis, these patients were treated as censored
observations. The median survival time for all patients was 69
months and the calculated 5-year survival rate was 52%.
Lavage evaluation
The lavage was carried out by introducing 500 ml of Ringer￿s
lactate into the upper abdomen immediately after opening the
abdominal cavity, followed by collection of five samples of 60 ml
each from the subphrenic space. For anticoagulation, EDTA at a
final concentration of 1 mg ml—1 was added.
The samples were centrifuged for 20 min at 1500 r.p.m.,
haemolysed with 15 ml ammonium chloride buffer (0.8%) and
washed with RPMI-1640 solution (ICN Biomedical, Ohio, USA).
Nine cytospins (Rotanta P, Hettich, Germany) were prepared with
approximately 4 ´ 104 cells per slide. The slides were dried
overnight at room temperature and fixed for 10 min in acetone
solution before staining or storage (—80°C). One slide was stained
with a modified rapid Giemsa/May—Gruenwald staining (Diff-
Quik; Baxter Diagnostics, Germany), and eight slides with the
alkaline phosphatase anti-alkaline phosphatase (APAAP) protocol
as previously described (Nakamura et al, 1994) with MCA Ber-
Ep4 (Dako, Hamburg, Germany) as the primary antibody in a 1:80
dilution followed by rabbit anti-mouse IgG secondary antibody (Z
259, Dako) in a 1:10 dilution with RPMI and inactivated human
serum at 1:8. The APAAP complex was used at a dilution of 1:160
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Figure 1 Kaplan–Meier curves (A) FPTC vs. overall survival for the 118
completely resected (R0) gastric carcinoma patients and (B) survival curves
divided according to pT category. (A) Of the 95 patients negative for FPTC,
36 died during the study period, resulting in a predicted 5-year survival
probability of 60%. Of the 23 FPTC-positive patients, 21 died during the
same period for a predicted 5-year survival probability of 8%. The differences
in survival for the FPTC-positive and FPTC-negative groups were statistically
significant (P = 0.0001). The dotted lines correspond to the 95% confidence
intervals. (B) None of the pT1 (early gastric carcinoma) cases had FPTC.
Within the pT2 category (no histological serosal tumour involvement), the
difference in survival between the FPTC-negative and FPTC-positive cases
was statistically significant (P = 0.02). The same was true for the cases with
histological serosal tumour involvement (pT3,4) (P = 0.001). For the FPTC-
negative subgroup (pT2 FPTC – and pT3,4 FPTC–), survival for the
subgroups with or without serosal tumour involvement was not statistically
different. This was also true for the FPTC-positive groups, although a
tendency (P = 0.09) towards a difference in survival was seen comparing
cases with or without serosal tumour involvement(Dianova, Hamburg, Germany). Meyer￿s haematoxylin was used
as the counterstain. Controls consisted of primary antibody omis-
sion [phosphate-buffered saline (PBS) buffer] as the negative
control and MOPC-21 (M-9269, Sigma, Munich, Germany) anti-
body 1:400 as a control for non-specific binding for each set of
reactions. Strong membrane and nucleus-associated granular cyto-
plasmic staining of cells by Ber-Ep4 was considered to be a posi-
tive reaction. In addition, to classify a sample as positive for
FPTC, the conventional cytological criteria of malignancy were
required to be present in a stained cell. On the basis of these
criteria, staining patterns were divided into four groups: negative
for Ber-Ep4, positive for Ber-Ep4 but lacking cytological criteria
of malignancy, isolated cells positive for Ber-Ep4 with cytological
criteria of malignancy and numerous cells [> 5 cells per high
power field (40´)] positive for Ber-Ep4 with cytological criteria of
malignancy.
Statistics
Comparison of frequency in group comparisons was performed
using the chi-squared test. The probability of survival was calcu-
lated for the different subgroups by the Kaplan—Meier method
(Kaplan and Meier, 1958). Statistical differences in survival were
evaluated by the log-rank test. All tests were performed at a signif-
icance level of P < 0.05. Prognostic factors were evaluated by
Cox￿s proportional hazard model with a log-linear risk function
(Cox, 1972). Covariate selection was carried out by a stepwise
forward procedure using the SPSS software package (SPSS,
Chicago, Illinois, USA).
RESULTS
Rate of FPTC
Three of 118 cases (3%) were diagnosed as having FPTC in lavage
by routine cytologic methods. Seven additional cases (6%) were
diagnosed as suspicious for FPTC and 108 (91%) were diagnosed
as negative. All three positive, four of the suspected and 16 of the
negative cases had FPTC by immunocytochemistry in the lavage
specimens, a total of 23 of the 118 (20%) cases. There were 17
additional cases (14%) in which cells with positivity for Ber-Ep4
were seen, but lacked the necessary cytological criteria of malig-
nancy. These cases were classified as negative for FPTC, and
consisted of cases in which staining for Ber-Ep4 was seen as weak
cell membrane staining of mesothelial cells or positively stained
debris within macrophages. Numerous cells (> 5 cells per high
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Table 3 Free peritoneal tumour cells compared with histopathology
Variable Patients FPTC
n (%) Negative Positive Positive P-value
nn (%)
WHO classification
Tubular 60 (51) 52 8 (13)
Papillary 7 (6) 5 2 (29)
Mucinous 2 (2) 2 0 –
Signet ring cell 32 (27) 24 8 (25)
Undifferentiated 17 (14) 12 5 (29) n.s.
Laurèn classification
Intestinal type 65 (55) 57 8 (12)
Nonintestinal type 53 (45) 38 15 (28) 0.03
Grade
G1,2 31 (27) 30 1 (3)
G3 70 (59) 52 18 (26)
G4 17 (14) 13 4 (24) n.s.
Primary tumour
lymphatic invasion
No 81 (69) 70 11 (14)
Yes 37 (31) 25 12 (32) 0.02
Perigastric adipose
tissue lymphatic
invasion
No 103 (87) 83 20 (19)
Yes 15 (13) 12 3 (20) n.s.
Perigastric adipose
tissue metastasis
No 112 (95) 93 19 (17)
Yes 6 (5) 2 4 (67) 0.003
Perineural invasion
No 110 (93) 88 22 (20)
Yes 8 (7) 7 1 (13) n.s.
Angioinvasion
No 114 (97) 92 22 (19)
Yes 4 (3) 3 1 (25) n.s.power field) were only found in two cases, both of which were also
positive by conventional cytology.
Comparison to TNM category (Table 1)
There were no positive pT1 cases. The proportion of positive cases
increased from pT2 (19%) to pT3 (41%) and decreased in the pT4
category (23%). The differences were significant. This may be
explained by cases in the pT4 category which had direct tumour
extension into neighbouring structures, but no exposed serosal
surfaces involved by tumour. The same correlation was also
reflected by the rates of FPTC in correlation with local tumour
invasion depth in the wall of the stomach from muscularis propria
(12%), subserosa (30%) and serosa (41%), whereas only 14% of
cases which infiltrated perigastric fatty tissue directly had free
tumour cells. The proportion of positive cases also increased
significantly according to pN category, with 6% of pN0 to 32% in
the pN2 cases. In the pM category, a higher percentage of pM1
(lymph) cases had FPTC, but this did not reach statistical signifi-
cance because of the small number of cases in this group.
Comparison to stage (Table 2)
There was a significance for increased incidence of FPTC with
advancing tumour stage. Further, within the pT2 or pT3 categories,
there was a marked increase in the frequency of FPTC with
increasing pN category. For example, in the pT2 category, there was
an increased rate of FPTC from 9% in the pN0 to 23% in the pN2
category, and for the pT3 category from 25% to 50% respectively.
Comparison to histological features (Table 3)
The presence of free metastases in perigastric adipose tissue,
which occurred in six cases (5%) seems to be associated with
FPTC (four out of six cases, 67%). Lymphatic vessel invasion at
the border of the primary tumour (primary tumour lymphatic inva-
sion) was diagnosed in 37 cases (31%) and was also positively
associated with FPTC (32% compared with 14%). As for the
Laur￿n classification, the non-intestinal type tumours had a signif-
icantly higher frequency of FPTC than the intestinal type tumours
(28% compared with 12%).
No correlation with the frequency of FPTC was seen according
to the site of the tumour, WHO histological classification, grade,
perineural or vessel invasion in the primary tumour or lymphatic
invasion of perigastric adipose tissue. However, the rate of FPTC
was significantly higher when more than two regions of the
stomach were involved by tumour (41% compared with 16%). In
the 47 cases (40%) with tumour size greater than 6 cm, signifi-
cantly more patients (30%) had FPTC than in the cases with a
smaller tumour (13%). Macroscopically diagnosed infiltration of
the serosa by the surgeon was also statistically significantly corre-
lated with a higher percentage of FPTC (7 out of 17 cases, 41%
compared with 16 of 101 cases, 16%). There was also a higher rate
of FPTC (4 out of 11 cases, 36%) of the exophytic type (Borrmann
type I) than the scirrhous infiltrating type (Borrmann type IV) (8
out of 20 cases, 40%) and the Borrmann types II and III (11 out of
68 cases, 16%), differences which were not statistically significant
however (results not shown).
Survival analysis
Overall, 21 of the 23 patients with FPTC (91%) and 36 of the 95
patients (38%) without FPTC died of tumour recurrence (P< 0.0001)
during the observation time. The median survival time for the FPTC-
positive patients was 11 months and for FPTC-negative patients
more than 72 months, with an estimated 5-year survival rate of 8%
and 60%, respectively, as calculated by Kaplan—Meier analysis
(Figure 1A).
Figure 1B shows the survival data divided according to pT cate-
gory. In the pT2 subgroup of 59 patients (without early carcinoma
and no histological serosal infiltration or perforation), there was a
significant survival advantage for the 48 FPTC-negative patients
compared with the 11 FPTC-positive patients. Of the 48 FPTC-
negative pT2 patients, 22 (46%) died because of tumour recur-
rence, with a median survival time of 70 months, compared with 9
out of 11 FPTC-positive pT2 patients (82%), who died with a
median survival of 11 months.
For the 35 pT3 and 4 patients (histological serosal tumour
involvement), an equally high survival difference was seen
between the FPTC-positive and -negative subgroups. The 23
FPTC negative pT3 and 4 patients (66%) had a median survival of
37 months and an estimated 5-year survival probability of 34%.
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Table 4 Multivariate survival analysis (Cox regression model) with grouped variables found to be significant by univariate analysis
Variable Category Univariate analysis Multivariate analysis Confidence interval
P-value*
P-value* Relative risk
Tumour (pT)* T1,2/T3,4 0.001 n.s. – –
Nodes (pN) N0/N1,2 < 0.0001 0.001 6.63 2.30–19.11
Metastasis [pM (lymph)] M0/M1 0.002 0.037 2.20 1.05–4.64
Laurèn classification Intestinal/ 0.05 n.s. – –
non-intestinal
Primary tumour Yes/no < 0.0001 n.s. – –
lymphatic invasion
Perigastric adipose tissue Yes/no 0.002 0.004 2.86 1.41–5.79
lymphatic invasion
Perigastric adipose tissue Yes/no 0.0001 n.s. – –
metastasis
FPTC Negative/positive < 0.0001 < 0.0001 4.48 2.34–8.57
*n.s, not significant (P > 0.05).There were 14 out of 23 (61%) recurrence-related deaths in this
group. All 12 of the FPTC-positive pT3 and 4 patients (34%) died
of tumour recurrence within the first 2 post-operative years.
After the first post-operative year, there was a tendency for
FPTC-positive but serosa-negative patients (pT2) to have a better
outcome than FPTC-positive patients with serosal involvement
(pT3 and 4). No prognostic difference was seen in the FPTC-nega-
tive group with regards to the presence or absence of serosal
involvement (Figure 1B).
Univariate and multivariate Cox analysis (Table 4)
The pT, pN and pM categories, the Laur￿n classification, involve-
ment of lymphatics (both in the primary tumour and perigastric
adipose tissue), free metastases in perigastric adipose tissue and
FPTC were found by univariate analysis to be significantly corre-
lated with survival. The Borrmann and WHO classifications,
perineural or vascular invasion, the site of tumour and the
surgeon￿s judgement of serosal tumour invasion were not corre-
lated with survival.
There was a significant survival advantage for the FPTC-nega-
tive compared with FPTC-positive patients in the subgroups: pN0,
pN+, pM0, stage I/II, stage III/IV, grades 3/4, intestinal Laur￿n
type, non-intestinal Laur￿n type, tumour diameter less than or
equal to 6 cm, tumour diameter greater than 6 cm, and the pres-
ence or absence of lymphangiosis (results not shown).
By multivariate Cox survival analysis, independent prognostic
factors for survival were pN category, FPTC, mesenteric
lymphatic vessel invasion, distant lymph node metastases [pM
(lymph)] in that order, with relative risk rates of 6.6, 4.5, 2.9 and
2.2 respectively (Table 4).
FPTC and recurrence pattern
Table 5 shows the clinically diagnosed site of first recurrence and
year of death for the 57 patients (48%) who died of recurrent
disease during the follow-up period. Two of the 23 FPTC-positive
patients (9%) are still alive after 51 and 70 months. These patients
were both staged pT2 pN2 pM0 with local wall invasion extending
to the subserosa and muscularis propria respectively. Thirty-six
patients (38%) of the FPTC-negative patients died of recurrent
tumour. For the 4-year follow-up period, the positive predictive
value of FPTC was 91% for death because of tumour recurrence,
whereas the negative predictive value was 62% for a tumour-free
survival. The sensitivity of FPTC for the prediction of tumour
recurrence was low at 37%, whereas its specificity of 97% was
very high. Comparing the follow-up years, twice as many patients
died in the first post-operative year (42%) as in the succeeding 3
years. After the first year, a constant death rate of approximately
20% was seen. Approximately one-third of the deaths were the
result of peritoneal carcinosis and one-third the result of distant
metastases respectively. Of the remaining one-third, two-thirds of
the patients had progression of tumour in the remaining lymph
nodes of compartment III or more distant lymph node regions, and
only a third were due to local recurrence. Of the patients who died
because of peritoneal carcinosis in the first year after surgery, there
was a significantly (P = 0.02) higher percentage of FPTC-positive
patients (8 out of 14, 57%) than FPTC-negative patients (1 out of
12, 8%). Within the subgroups pT2 and pT3 and 4, the same statis-
tical relation was seen. However, only 10 out of 18 patients (55%)
who died because of peritoneal carcinosis had FPTC in their
lavage specimens. After the first year of follow-up, there was no
longer a correlation between the site of recurrence and the finding
of FPTC.
DISCUSSION
FPTC: frequency, conventional cytology
The detection of isolated tumour cells for the diagnosis of malig-
nant ascites is a routine procedure in the clinical practice of
oncology and is a finding which is equivalent to the diagnosis of
disseminated peritoneal carcinosis. Prognostically, such a peri-
toneal carcinosis represents an incurable situation for gastro-
intestinal carcinoma (Spratt, 1986; Parsons et al, 1996).
Approximately 40—50% of patients who have a resection for
gastric carcinoma have local infiltration of the gastric serosa
(Nakamura et al, 1992; Roder et al, 1993), and one might expect
that cells from the gastric serosa would desquamate into the peri-
toneal space and be cytologically detectable in most of these cases
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Table 5 Comparison of FPTC with year of death and location of relapse
Year of death: Year 1 Year 2 Year 3 Year 4
Location Patients FPTC – FPTC + FPTC – FPTC + FPTC – FPTC + FPTC – FPTC +
n (%) n = 12 n = 14 n = 11 n = 3 n = 7 n = 4 n = 65 n = 2
Relapse 57 (48) [24 (42%)] [12 (21%)] [11 (19%)] [10 (17%)]
Peritoneal 18 (32) 1 8 3 1 2 1 2 –
carcinosis
Lymph node 13 (23) 3 2 3 1 2 – 2 –
metastasis
Distant 18 (32) 4 4 2 1 1 3 3 –
metastasis
Extraluminal 5 (9) 1 – – – 1 – 3 –
relapse
Intraluminal 3 (5) 1 – 1 – 1 – – –
relapse
No relapse 61 (52) 2a –2 a – – – 52 + 3a 2
aDeath of other causes.(Kiyasu et al, 1981). However, it has been demonstrated in cases
of definite tumour involvement of the gastric serosa without
metastatic peritoneal implants, that only from 12% (Bonenkamp et
al, 1996) to 22% (Chen and Liu, 1994) of cases have detectable
free tumour cells. With an established peritoneal carcinosis, the
rate of positive cytological diagnoses ranges from 50% (Jaehne et
al, 1989) to 81% (Kaibara et al, 1987), with the provision that the
rate of positive diagnosis is dependent on the extent of peritoneal
carcinosis and, more importantly, on the presence of ascites.
In our study, we found a rate of FPTC in conventional cytology
of 3% with an additional 6% of cases which were diagnosed as
suspicious for malignancy. In a subgroup of the Dutch Gastric
Cancer Study (Bonenkamp et al, 1996), which is presently the
single largest study of this topic in the Western world, among
completely (R0-UICC) resected patients, there was detection rate
of FPTC in 4% of patients, with an additional 1% diagnosed as
suspicious for malignancy. In a smaller series, in tumours operated
upon according to the guidelines of the GGCS (Roder et al, 1995),
as was our study, Jaehne et al (1989) found a rate of 11% for
FPTC. In the remaining studies of FPTC in gastric carcinoma,
which are almost exclusively from Asia, rates of 14% (Koga et al,
1984) and 22% (Chen and Liu, 1994) are quoted for patients who
have had a ￿curative￿ resection according to the guidelines of the
JRSGC (Japanese Research Society for Gastric Cancer, 1981). In
patient collectives with ￿non-curative￿ resections (R1, 2-UICC),
rates of FPTC ranging from 23% (Bonenkamp et al, 1996) to 59%
(Ikeguchi et al, 1994) have been found.
In contrast, FPTC can be found in cases with a normal-
appearing gastric serosa and a complete gastric resection. In the
series of Bonenkamp (1996), in which there were 217 patients, a
rate of 1% FPTC was found in such cases. In clinically suspicious,
but histologically non-infiltrated serosa (S1 according to the
JRSGC), rates for comparable patient groups of 3% (Koga et al,
1984; Boku et al, 1990) have been reported, whereas others found
no positive cases (Chen and Liu, 1994).
Two pathogenetic mechanisms can be hypothesized to explain
the finding of FPTC even when the local gastric serosa is not histo-
logically involved by tumour. First, small numbers of individual
tumour cells, not detectable by routine histological methods, could
be desquamated into the peritoneum from the serosa adjacent to
the tumour (Kiyasu et al, 1981). Alternatively, spread of tumour
cells in the mesenteric lymphatics with seeding into the peritoneal
space through so-called ￿gaps￿ in the mesenteric lymphatics in
association with milky spots has been hypothesized (Spratt, 1986;
Hagiwara et al, 1993). In contrast, as mentioned above, not every
case in which the serosa is involved by tumour shows FPTC. It is
probable that not every tumour cell on the serosal surface can
detach itself, and, even once it is shed, have the ability to survive
in the peritoneal space.
FPTC: immunocytology
In our study, we achieved a tripling of the detection rate of positive
cases to 20% in comparison with conventional cytology. This is in
line with previous studies which generally have reported a factor
of two- to threefold over conventional cytology for tumour cell
detection in effusions (Johnston et al, 1987; Lidang Jensen and
Johansen, 1994). Among the various antibodies which have been
used, Ber-Ep4 (Latza et al, 1990) has shown itself to be highly reli-
able for the detection of epithelial tumour cells, with a sensitivity
of 83—100%, a positive predictive value of 96%, and a false-posi-
tive rate of 2—7% (De Angelis et al, 1992; Stoop et al, 1992; Diaz-
Arias et al, 1993; Robinson and Royston, 1993; Lidang Jensen and
Johansen, 1994).
Juhl et al (1994) and Broll et al (1996) were among the first to
report results with immunocytology in peritoneal lavage speci-
mens for a variety of gastrointestinal carcinomas. They used a
panel of multiple antibodies [carcinoembryonic antigens (CEA),
cytokeratins, mucin antibodies, etc.] and found rates of FPTC of
43% and 69%, respectively, including up to 25% positivity in early
carcinomas. In these studies, however, positivity was defined
solely as positive staining of cells regardless of cytological
features, and correlation with prognosis was not reported.
Our FPTC-positive cases included 57% of the cases which had
been classified as suspicious and 13.5% of the cases classified as
negative by conventional cytology. These patients showed the
same poor prognosis as those which had been classified as positive
by conventional cytology. In our study, we also required that the
positively stained cells had cytological features of malignancy to
avoid false-positive results. In 14% of our cases, we observed
clusters of obvious mesothelial cells with a positive, strongly
membrane-based stain. Because most of these cases had invasion
of the primary tumour to the subserosa, this phenomenon could be
due to the epithelial glycoprotein antigen expressed by tumour
cells which was bound by membrane proteins of the mesothelial
cells in the process of adhesion. Epithelial glycoprotein (Egp-34)
has not been reported to be expressed by mesothelial cells them-
selves (Latza et al, 1990). Another, more frequent, finding was
Ber-Ep4 staining in macrophages, which would also have been a
source of false-positive diagnoses if cytological criteria for malig-
nancy had not been used to identify the tumour cells.
Correlation of FPTC with histopathological features
All previous studies of FPTC in gastric carcinoma have shown a
strong correlation between the extent of local tumour infiltration of
the gastric serosa and the FPTC rate. When tumour infiltration of
the gastric serosa was measured planimetrically (Kaibara et al,
1987), a significant difference was found between 10—15 cm2 and
20 cm2. In the subgroup T3 N0—2 M0, Abe et al (1995) found a
prognostically relevant cut-off point of 3 cm diameter (histologi-
cally determined) tumour serosal involvement, for which the rate of
FPTC rose from 7% to 32%. Bonenkamp et al (1996) could show
that the risk for the development of FPTC was most strongly depen-
dent on serosal involvement by a factor of 11 in comparison with
lymph node status or stage. We found a positive correlation
between tumour diameter (< 6 cm vs. > 6 cm) and the rate of FPTC.
As in our study, no previous study using conventional cytology
has found FPTC in early gastric carcinoma. Juhl et al (1994) and
Broll et al (1996) found rates of FPTC of up to 25% in their cases
of early gastric carcinoma, which might be explained by a high
false-positive rate.
The positive correlation between FPTC and lymph node status,
which we found, has been previously reported by several authors
(Chen and Liu, 1994; Ikeguchi et al, 1994; Juhl et al, 1994; Abe et
al, 1995; Bonenkamp et al, 1996).
Our study showed a correlation between undifferentiated, non-
intestinal or infiltrative classified gastric carcinoma and a higher
rate of FPTC. Previous studies have shown a similar correlation
between FPTC and the histological classification of the carcinoma
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1994; Ikeguchi et al, 1994) or the WHO classification as modified
by Sugano (Boku et al, 1990; Iitsuka et al, 1990; Chen and Liu,
1994; Ikeguchi et al, 1994). As in our study, higher rates of FPTC
have also been found in the literature for macroscopic Borrmann
type IV tumours (Chen and Liu, 1994), but no correlation between
FPTC and grade, perineural invasion or vascular invasion has been
described in the literature. The positive correlation between FPTC
and lymphangiosis in the primary tumour or presence of free
metastases in the perigastric adipose tissue has not been previously
described.
Impact of FPTC on survival
We found 5-year survival rates for FPTC-positive compared with
FPTC-negative groups of 8% and 60%, similar to most previous
studies in which the survival rates for FPTC-positive patients with
￿curative￿ or R0-UICC resections have been found to range
between 13% (Koga et al, 1984) and 25% (Boku et al, 1990; Chen
and Liu, 1994) compared with FPTC-negative patients who had 5-
year survival rates of between 46% (Chen and Liu, 1994) and 54%
(Boku et al, 1990). Of the five studies in which a univariate
survival analysis was carried out to determine the impact of FPTC,
only Abe et al (1995) found no significant difference in survival.
No difference in prognosis has been seen in comparison with the
numbers of free tumour cells or whether or not the tumour cells
were found in clusters or as single cells (Iitsuka et al, 1990).
In the analysis of our subgroups with or without a histologically
confirmed involvement of the serosa, we found FPTC in 19% of
those with an unremarkable serosa. In terms of survival, FPTC
proved to be a more important factor than serosal involvement
because, within the FPTC-positive and FPTC-negative subgroups,
the presence or absence of serosal involvement had no further
impact on prognosis when cases of early gastric carcinoma were
excluded. In contrast, the prognosis of all FPTC-positive patients
corresponded to the prognosis of patients in our study with pM1-
(lymph), who had a median survival time of 27 months.
By multivariate analysis, detection of FPTC was the second
strongest prognostic factor after lymph node status. A comparable
multivariate analysis has not yet been reported in the literature. In
contrast to the results of Abe et al (1995), FPTC was also a highly
significant prognostic factor for T3 N0—2 M0 patients in the
analysis of our subgroups.
FPTC and pattern of tumour recurrence
In our study, 57% of the patients who died within the first post-
operative year as a result of peritoneal carcinosis had had FPTC.
This pattern was significantly different from FPTC-negative cases.
However, after the first year, there was no difference in the pattern
of tumour recurrence between FPTC-positive and -negative cases.
Other studies have also reported that gastric carcinoma patients
with free tumour cells in their lavage specimens have, after cura-
tive resection, a high likelihood of developing a peritoneal carci-
nosis (Koga et al, 1984). Again, this is in contrast to the study of
Abe et al (1995), who found no correlation between FPTC and
recurrence in the form of peritoneal carcinosis (30% in his study).
The FPTC-positive patients in our study who died within the
first year were not characterized by particular histopathological or
staging parameters, so that they cannot have been identified with
any conventional prognostic factors.
CONCLUSION
Using immunocytology, we found FPTC to have a strong negative,
independent impact in patients who had a complete resection of
their gastric carcinoma, with an impact similar to the presence of
distant nodal metastases (pM1 lymph). A particularly important
finding of our study in this regard lies in the detection of FPTC and
its attendant poor prognosis in 19% of patients without histolog-
ical serosal involvement by tumour. Although some authors have
recommended the planimetric measurement of tumour involve-
ment of the serosa, our results show that the finding of FPTC has
an even greater impact. Boku et al (1990) demonstrated that the
prognosis of FPTC-positive patients was similar to that of patients
who had a metastatic peritoneal carcinosis (P1,2-JRSGC). This
indicates that, in some FPTC-positive cases, a so-called ￿occult
peritoneal carcinosis (Kiyasu et al, 1981) is present, perhaps repre-
sented in our study by the subgroup of FPTC-positive patients who
died in the first post-operative year and had a very high risk for the
development of peritoneal carcinosis. In other cases, FPTC seems
to carry a risk of distant metastatic disease similar to the impact of
isolated tumour cells in the bone marrow (Jauch et al, 1996).
On the basis of our findings, we believe that the detection of
FPTC might form an important component of preoperative staging,
especially when the option of neoadjuvant therapy is to be consid-
ered. Our results strongly support the recommendation of the UICC
that cases with FPTC should be designated as ￿pM1￿ or, in cases of
an otherwise complete resection, that the designation ￿R1c￿ be used
because this has a strong impact on the prognosis of the patient.
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